The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Also received tentative approval for 137 mg
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Valbenazine Capsules had annual sales of US $1,993.6 mn in the United States (IQVIA MAT June 2024)
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Subscribe To Our Newsletter & Stay Updated
